Vasculitis & polymyalgia rheumatica
Mepolizumab exerts crucial effects on glucocorticoid discontinuation in patients with eosinophilic granulomatosis with polyangiitis: a retrospective study of 27 cases at a single center in Japan
Authors' conclusion
After three years of treatment with mepolizumab, approximately 50% of patients with EGPA achieved GC-free status.
Study context
- Population
- Eosinophilic granulomatosis with polyangiitis (EGPA) patients treated with mepolizumab who were on glucocorticoid (GC) at mepolizumab induction, single centre in Japan, as of January 2023
- Participants
- 27 patients
- Exposure
- Patients who discontinued GC vs those who continued GC on mepolizumab
- GC-freen = 13
- Outcome
- Efficacy of mepolizumab (GC discontinuation) and factors contributing to GC discontinuation
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
GC-free status · median 31 months of mepolizumab
GC-free
48%
13
Observational data: associations, not effects.
Further findings
Absolute eosinophil counts at diagnosis (univariate analysis) · EGPA diagnosis · multivariate analysis showed no significant differences
P = 0.037
Gastrointestinal lesions (univariate analysis) · multivariate analysis showed no significant differences
P = 0.025
Duration of mepolizumab treatment at the time of the study
- Median duration of mepolizumab, months (IQR, 26 to 40)
- 31
Daily prednisolone dose at the time of the study
- Median daily prednisolone dose, mg (IQR, 0 to 1.8)
- 1
Vascular Damage Index (VDI) in GC-continue
- Mepolizumab significantly improved VDI in the GC-continue group (P = 0.004)
Original publication
Mepolizumab exerts crucial effects on glucocorticoid discontinuation in patients with eosinophilic granulomatosis with polyangiitis: a retrospective study of 27 cases at a single center in Japan. Arthritis Res Ther. Published 26 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →